Endo Must Face Stock-Drop Claims In Opioid Safety Suit
Endo International PLC and several of its executives must face an investor suit alleging the company knowingly misrepresented the safety of its Opana opioid, leading to a significant stock drop when...To view the full article, register now.
Already a subscriber? Click here to view full article